Plain-English translation of NCT02443831 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of immunotherapy that uses your own immune cells to fight acute lymphoblastic leukemia (ALL). Your immune cells are collected, trained in the laboratory to recognize and attack leukemia cells, and then given back to you. The study will measure how safe and effective this treatment is for children and young adults with high-risk or relapsed leukemia.
Children and young adults with relapsed or high-risk ALL often have limited treatment options, and their disease is harder to cure with standard chemotherapy alone. This medication represents a new approach using the body's own immune system to potentially offer better outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, doctors will first collect some of your blood cells in a procedure called leukapheresis. Your cells will be sent to a laboratory where they are modified and grown into CAR T-cells. While the cells are being prepared, you will receive chemotherapy and radiation to prepare your body. Once the cells are ready, they will be infused back into you. You will then be closely monitored over time to see how well the treatment works and to check for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United Kingdom